Cargando…

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level

Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalopathy. Exposure to John Cunningham virus (JCV) is a prerequisite for PML (progressive multifocal leukoencephalopathy). To assess JCV exposure in multiple sclerosis patients, we performed a serological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanzillo, Roberta, Liuzzi, Raffaele, Vallefuoco, Luca, Moccia, Marcello, Amato, Luca, Vacca, Giovanni, Vacchiano, Veria, Portella, Giuseppe, Brescia Morra, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199559/ https://www.ncbi.nlm.nih.gov/pubmed/25328396 http://dx.doi.org/10.2147/TCRM.S63295

Ejemplares similares

Kidney Allograft Dysfunction Due to John Cunningham (JC) Virus Nephropathy
por: Sharma, Neeraj, et al.
Publicado: (2022)

Genotypes of John Cunningham (JC) Virus Urinary Excretion in Pregnant and Non-Pregnant Women in Isfahan, Iran
por: Atyabi, Sayyedeh Rahmaneh, et al.
Publicado: (2018)

Progressive Multifocal Leukoencephalopathy in a Lung Transplant Recipient: Isolation of John Cunningham (JC) Virus from Bronchoalveolar Lavage
por: Panchabhai, Tanmay S., et al.
Publicado: (2016)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
por: Mancuso, Roberta, et al.
Publicado: (2012)

John Cunningham
Publicado: (1919)

Daniel John Cunningham
Publicado: (1909)

Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy
por: Clausi, Valeria, et al.
Publicado: (2015)

Johns and Cunningham’s the Physics of Radiology
por: Sharma, Sunil Dutt
Publicado: (2021)

Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon
por: Lanzillo, Roberta, et al.
Publicado: (2013)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Mapping the history and current situation of research on John Cunningham virus – a bibliometric analysis
por: Zheng, Hua-chuan, et al.
Publicado: (2009)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

COS-7-based model: methodological approach to study John Cunningham virus replication cycle
por: Prezioso, C., et al.
Publicado: (2018)

High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis
por: Kim, Su-Hyun, et al.
Publicado: (2019)

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015
por: Moccia, Marcello, et al.
Publicado: (2017)

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
por: Moccia, Marcello, et al.
Publicado: (2020)

Favorable Response to Mirtazapine in John Cunningham Virus-related Gray Matter Lesion in a Patient with Human Immunodeficiency Virus
por: Alwehaibi, Abdullah I, et al.
Publicado: (2019)

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
por: Moccia, Marcello, et al.
Publicado: (2020)

Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10
por: Moccia, Marcello, et al.
Publicado: (2019)

Erratum to: High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis
por: Kim, Su-Hyun, et al.
Publicado: (2020)

A Case of John Cunningham Virus Induced Rhombencephalitis after Rituximab Therapy for Idiopathic Thrombocytopenic Purpura
por: Katragadda, Silpita, et al.
Publicado: (2021)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study
por: Pontillo, Giuseppe, et al.
Publicado: (2017)

Determinants of early working impairments in multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2022)

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus
por: Zingaropoli, Maria A., et al.
Publicado: (2018)

Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review
por: De Angelis, Marcello, et al.
Publicado: (2021)

Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica
por: Paz, Sonia Patricia Castedo, et al.
Publicado: (2018)

High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis
por: Lau, Alexander, et al.
Publicado: (2018)

Internal Jugular Vein Blood Flow in Multiple Sclerosis Patients and Matched Controls
por: Mancini, Marcello, et al.
Publicado: (2014)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak
por: Buonomo, Antonio, et al.
Publicado: (2020)

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate
por: Farley, Stephen, et al.
Publicado: (2019)

Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis
por: Petracca, Maria, et al.
Publicado: (2021)

Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis
por: Caliendo, Daniele, et al.
Publicado: (2023)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12urb694dn4k3mcte6ros41t2t